Navigation Links
CoAxia Announces Completion of Enrollment in Ischemic Stroke Trial

MINNEAPOLIS, Feb. 12 /PRNewswire/ -- CoAxia™, Inc. of Maple Grove, MN, announced today the completion of enrollment in its SENTIS randomized, controlled, pivotal trial of NeuroFlo™ Perfusion Augmentation Therapy as an acute interventional treatment for ischemic stroke.  The Company plans to complete data collection and analysis of results in Q3 of 2010 and, if warranted, submit a PMA to the US FDA.

Ischemic stroke is one of the largest causes of death and disability in the western world, affecting over 650,000 patients annually in the United States alone, and responsible for $70B in annual costs for the long term care of stroke-disabled patients.  Whereas in the US approximately 5% of ischemic stroke patients are treated acutely, CoAxia believes that if the NeuroFlo treatment proves safe and effective, as many as 50% of stroke patients may become eligible for treatment – a significant potential benefit to stroke patients and the healthcare system.

The SENTIS trial is being performed in the US and Europe under an FDA IDE, and includes ischemic stroke patients treated within 14 hours of the onset of symptoms.  By comparison, the only other approved stroke therapy in the US is the intravenous delivery of the thrombolytic drug tPA, which is approved for a three hour time window.  SENTIS is a 1:1 randomized, controlled study with a neurological improvement endpoint measured at 90 days after symptom onset.  The outcome measure is the Stroke Global Score as defined by the National Institute of Neurological Disease and Stroke (NINDS). With 515 patients enrolled at over 50 stroke centers in 10 countries, CoAxia believes that it will have sufficient patients and site diversity to accurately measure safety and efficacy of the NeuroFlo technology in a broad segment of ischemic stroke patients.

Professor Ashfaq Shuaib, Director of Stroke Services at the University of Alberta Medical Center, and Principal Investigator of the SENTIS trial commented; "The SENTIS trial will provide the safety and efficacy data which stroke neurologists demand for adoption of a new stroke therapy: randomized, controlled data with a 90 day neurological endpoint.  CoAxia has conducted this study at the highest level, and I am confident that the quality of the data, if the trial proves positive, will allow clinical adoption of this exciting new technology."

Lorinda Austin, Vice President of Clinical Affairs commented, "The SENTIS trial is a collaboration between CoAxia and stroke researchers from the US, Canada, Europe and Israel.  Completion of enrollment of 515 patients is a key milestone for the trial.  It indicates the worldwide clinical interest in the technology, and it signals our new focus: to complete patient data collection and determine our safety and efficacy profile."

Andrew M. Weiss, President and CEO commented, "CoAxia has invested more than 4 years and over $40M in the SENTIS trial, and we are excited about the ability to determine the safety and efficacy outcomes of the SENTIS trial later this year.  If positive, we will have plans in place to submit our PMA to the FDA as well as initiate commercialization in Europe and around the world."

CoAxia, Inc. is a venture-backed, privately held, clinical-stage company focused on providing perfusion augmentation therapies that improve outcomes for patients with cerebral ischemia resulting from stroke, vasospasm and other conditions.

SOURCE CoAxia, Inc.



SOURCE CoAxia, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Announces Unaudited Fourth Quarter and Full Year 2009 Results
2. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2009 Earnings Conference Call and Webcast
3. Moleac Announces Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD
4. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
5. Kinexus Announces the Launch of a New Protein Kinase Microarray
6. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
7. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
8. Silicon Kinetics Announces New Biosensor Chips With Wide Palette of Surface Chemistries
9. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
10. Healthcare Data Solutions Announces Expansion of its Healthcare Customer Solutions Team With Two Key Additions
11. Angiotech Pharmaceuticals Announces Conference Call and Webcast
Post Your Comments:
(Date:10/12/2015)... de octubre de 2015 El 8 de ... un récord en el congreso con su declaración acerca ... International Plasma Awareness Week (IPAW), que se celebrará del ... por la Plasma Protein Therapeutics Association (PPTA) ... , Aumentar la concienciación mundial acerca de la ...
(Date:10/12/2015)... , October 12, 2015 LabStyle ... Diabetes Management Solution, today announced its Medical Director, Dr. ... study at MobiHealth,s 5th EAI International Conference on ... healthcare through innovations in mobile and wireless technologies," the ... from October 14 - 16, 2015. The ...
(Date:10/12/2015)... ... October 12, 2015 , ... Dr. Carl Peck, MD, ... the firm as a Premier Expert consultant. NDA Partners Premier Experts are ... value to the company's clients. Premier Experts collaborate to design and implement ...
(Date:10/11/2015)... ... October 11, 2015 , ... Intelligent Implant Systems, ... launched and multiple surgeries have been completed with this new posterior thoracolumbar spinal ... & Spine Center of the Carolinas. The Revolution™ Spinal System pioneers a ...
Breaking Biology Technology:
(Date:10/12/2015)... Research and Markets ( ) ... Recognition Market by Component (Hardware & Software), Product ... Industry (Travel & Immigration, Military & Defense, & ... report to their offering. ... Market worth 3627.90 Million USD by 2020 ...
(Date:10/7/2015)... 8, 2015 --> ... Cards (FPC) during third quarter 2015 amounted to around 960 ... 860 MSEK that was communicated 20 August 2015. ... delivery capacity and a continued growing demand for the company,s ... to be higher than during the third quarter. The revenue ...
(Date:10/2/2015)... ) has ... Law Using Biometrics" report to their offering. ... addition of the "Enforcing the Law Using ... Research and Markets ( ) has ... Law Using Biometrics" report to their offering. ...
Breaking Biology News(10 mins):